ENहिन्दी soon
Home/India/Answers/What is the MRP of Mounjaro in India?
INIndia Prices

What is the MRP of Mounjaro in India?

GLP Guidebook teamUpdated 5 Oct 202615 sourcesWritten from published sources
The short answer

A Mounjaro (tirzepatide) KwikPen in India has a printed MRP of ₹13,125 to ₹25,781, checked on 5 October 2026. The 2.5 mg pen costs least; 12.5 and 15 mg cost most. Each pen holds 4 weekly doses. A year on 5 mg throughout is about ₹2.13 lakh. Today's MRPs equal the launch MRPs less the GST cut of September 2025.

Before you go further
  • Mounjaro, like other GLP‑1 medicines, is prescription-only in India, not sold over the counter.8
  • A government statement on 1 Apr 2026 said only endocrinologists, internal-medicine specialists and cardiologists can prescribe them.8 CDSCO expert-committee minutes attach a similar condition to some approvals (endocrinologist or internal-medicine specialist), but we found no rule covering every brand.9
  • These are printed MRPs (maximum retail price), the list price on the pack. We never quote a seller's discount price.
  • To check that a pen is genuine, see Fake Ozempic and Mounjaro pens. The risks are in Guide 5: Side effects and risks.
  • Nothing here promises any result, and nothing here is for sale.

What is the MRP of each Mounjaro strength?

Each Mounjaro KwikPen holds 4 weekly doses, and its printed MRP rises with the strength, from ₹13,125 to ₹25,781.

Two pharmacy listings agree on all 6 strengths, checked 5 October 2026.1 7.5 and 10 mg share a price, as do 12.5 and 15 mg.

StrengthMRP per pen (4 doses)Per weekly dose52 weeks (13 pens)
2.5 mg₹13,125₹3,281₹1,70,625
5 mg₹16,406₹4,102₹2,13,278
7.5 mg₹20,625₹5,156₹2,68,125
10 mg₹20,625₹5,156₹2,68,125
12.5 mg₹25,781₹6,445₹3,35,153
15 mg₹25,781₹6,445₹3,35,153

Printed MRPs from two pharmacy listings, checked 5 Oct 2026.1 The last two columns are our arithmetic: pen ÷ 4, and pen × 13.

Mounjaro also comes as single-dose vials, listed at 2.5 mg (MRP ₹3,281) and 5 mg (₹4,102) only.2 Four vials cost the same as one pen of that strength.

What does a year of Mounjaro cost?

We count a year as 52 weekly doses, or 13 pens, so 12 months on 5 mg throughout costs about ₹2.13 lakh at today's MRP.

A month is about 4.3 weekly doses (52 ÷ 12), so by our arithmetic about ₹14,200 at 2.5 mg and ₹17,800 at 5 mg.1

Your doctor sets the dose. The US label starts at 2.5 mg. It allows a 2.5 mg rise after at least 4 weeks, up to 15 mg.7 The dose steps are in Mounjaro doses explained. Here are two worked examples at today's MRPs.

  • One pen at 2.5 mg, then 12 pens at 5 mg, costs ₹2,09,997 (about ₹2.1 lakh).1
  • One pen at each step up to 12.5 mg, then 8 pens at 15 mg, costs ₹3,02,810 (about ₹3 lakh).1

That is the medicine alone. An endocrinologist's in-clinic fee had a median of ₹1,100 on Practo in 6 cities.10

Standard health insurance usually pays only for hospital admission, so monthly medicines like this are rarely covered.15 See Guide 6 and Does health insurance cover GLP-1 medicines in India?

Work out a full year's cost

Medicine, doctor visits and tests, in ₹. Free, no sign-up.

Open the calculator

Why is Mounjaro's MRP lower than its launch price?

GST on most medicines fell from 12% to 5% on 22 September 2025, and today's printed MRPs equal the launch MRPs less that tax cut.

Lilly launched the KwikPen in August 2025 at ₹14,000 for a 2.5 mg pen (4 weekly doses), which Business Standard called a month's supply. The 12.5 and 15 mg pens were ₹27,500.3 The vials launched in March 2025 at ₹3,500 (2.5 mg) and ₹4,375 (5 mg).4 After the GST cut,5 the price regulator, NPPA, told makers to issue revised MRPs.6

Swap 12% tax for 5% on ₹14,000 (× 105/112) and you get ₹13,125, today's MRP.1,3 That is our arithmetic; we found no Lilly statement of the new figures. We also found no report of a Mounjaro price cut since.

Is there a cheaper generic Mounjaro in India?

No. We found no generic tirzepatide on sale in India, and Lilly's main tirzepatide patent there is expected to last until 2036.

The Medicines Patent Pool says the main patent is granted in India. It expects formulation patents to run to 2039 across lower- and middle-income countries.11 Yurpeak, sold by Cipla, is not a generic. Lilly makes it, and Cipla said it would cost the same as Mounjaro.12

The cheaper generics that launched in March 2026 are semaglutide, a different medicine.13 Their prices are in Guide 6.

RisksThe risks, in brief
  • Nausea is very common (more than 1 in 10) on the EU Mounjaro label.14 In the US label's diabetes trials, 12% to 18% felt sick on Mounjaro, vs 4% on a dummy injection.7
  • A swollen pancreas (pancreatitis) and gallstones are uncommon (1 in 100 to 1 in 1,000) on the EU Mounjaro label, and both are label warnings.7,14
  • Losing fluid from vomiting or diarrhoea can strain the kidneys. Both labels warn about this.7,14 See GLP-1s and kidneys.
  • Low blood sugar (hypos) is more likely with insulin or a sulfonylurea.7
  • Thyroid C-cell tumour warning. The US label rules it out with a personal or family history of a rare thyroid cancer (MTC) or MEN 2.7
  • Not recommended in pregnancy on the EU label. The US label says it can make the contraceptive pill less reliable after starting and after each dose rise.7,14 See GLP-1s, pregnancy and contraception.
Full detail in Guide 5: Side effects and risks →

Read the full picture

Related questions

Is Mounjaro available in India? Is there a generic Mounjaro (tirzepatide) in India? What is tirzepatide? What is the MRP of Ozempic in India? Do you need a prescription for GLP-1 medicines in India?

Where these prices come from

Every price we found for each pack, by source, A to Z. When sources agree, we show that price. When they don't, we show the range. A crossed-out price is one we left out, with the reason when you hover over it. We never link to sellers, and the order isn't a recommendation.

Mounjaro KwikPen

DoseMRP shown (4 weekly doses)Each source, A to Z, as listed
2.5 mg₹13,125MrMed: ₹13,125 a pen of 4 doses (5 Oct 2026)
PharmEasy: ₹13,125 a pen of 4 doses (11 Oct 2026)
Tata 1mg: ₹13,125 a pen of 4 doses (5 Oct 2026)
5 mg₹16,406MrMed: ₹16,406.25 a pen of 4 doses (11 Oct 2026)
PharmEasy: ₹16,406 a pen of 4 doses (11 Oct 2026)
7.5 mg₹20,625MrMed: ₹20,625 a pen of 4 doses (5 Oct 2026)
PharmEasy: ₹20,625 a pen of 4 doses (11 Oct 2026)
10 mg₹20,625MrMed: ₹20,625 a pen of 4 doses (5 Oct 2026)
PharmEasy: ₹20,625 a pen of 4 doses (11 Oct 2026)
12.5 mg₹25,781MrMed: ₹25,781.25 a pen of 4 doses (5 Oct 2026)
PharmEasy: ₹25,781 a pen of 4 doses (11 Oct 2026)
15 mg₹25,781MrMed: ₹25,781.25 a pen of 4 doses (5 Oct 2026)
PharmEasy: ₹25,781 a pen of 4 doses (11 Oct 2026)
Tata 1mg: ₹25,781 a pen of 4 doses (5 Oct 2026)

Mounjaro single-dose vials

DoseMRP shown (4 weekly doses)Each source, A to Z, as listed
2.5 mg₹13,125MrMed: ₹3,281.25 a vial (5 Oct 2026)
PharmEasy: ₹3,281 a vial (11 Oct 2026)
Tata 1mg: ₹3,281.25 a vial (5 Oct 2026)
5 mg₹16,406MrMed: ₹4,101.56 a vial (11 Oct 2026)
PharmEasy: ₹4,102 a vial (11 Oct 2026)
Did this answer your question?

Sources

  1. PharmEasy Mounjaro price page (updated 1 Oct 2026) and MrMed product listings (updated 26 Sep 2026), printed MRP of Mounjaro KwikPens, 4 weekly doses each: 2.5 mg ₹13,125; 5 mg ₹16,406 (MrMed ₹16,406.25); 7.5 and 10 mg ₹20,625; 12.5 and 15 mg ₹25,781 (MrMed ₹25,781.25). Pharmacy listings, used only for the printed MRP, checked 5 Oct 2026.
  2. PharmEasy Mounjaro price page (updated 1 Oct 2026) and MrMed product listings (updated 26 Sep 2026), printed MRP of Mounjaro single-dose vials: 2.5 mg ₹3,281 (MrMed ₹3,281.25); 5 mg ₹4,102 (MrMed ₹4,101.56). Pharmacy listings, used only for the printed MRP, checked 5 Oct 2026.
  3. Business Standard (citing Reuters). Mounjaro KwikPen by Lilly debuts in India at ₹14,000 for diabetes, obesity, 13 Aug 2025. business-standard.com
  4. Business Standard (with Reuters). Eli Lilly launches blockbuster anti-obesity drug Mounjaro in India, 20 Mar 2025 ("priced at Rs 3,500 for a 2.5 mg vial and Rs 4,375 for a 5 mg vial"). business-standard.com
  5. Press Information Bureau, Ministry of Finance. Recommendations of the 56th meeting of the GST Council, 3 Sep 2025 ("Reduction of GST on all other drugs and medicines from 12% to 5%"; goods from 22 Sep 2025). gstcouncil.gov.in (PDF)
  6. National Pharmaceutical Pricing Authority (NPPA). Office memorandum F. No. 12(24)/2021/DP/NPPA/Div.II(Vol.II)-Part(1), 13 Sep 2025, revising the OM of 12 Sep 2025: makers to issue revised price lists "reflecting the revised GST rates and Revised MRP". nppa.gov.in (PDF)
  7. Eli Lilly. Mounjaro (tirzepatide) US prescribing information, revised 08/2026. US label, not the Indian one: we found no public Indian label. Sections 2.1, 4, 5.1, 5.2, 5.3, 5.5, 5.8, 6.1 (Table 2), 7.2, 8.1 and the boxed warning. pi.lilly.com
  8. PIB Research (Government of India). GLP-1 Drugs: Use, Risks, and Regulation. Backgrounder, 1 Apr 2026. pib.gov.in (PDF)
  9. CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), 100th meeting, 20–21 Apr 2023, item 1 (tirzepatide, Eli Lilly). Committee minutes, not the final permission. cdsco.gov.in (PDF) · archived copy
  10. Practo. Endocrinologist listings, first page of results, in-clinic consultation fee, in Delhi, Mumbai, Bengaluru, Chennai, Hyderabad and Kolkata: 59 doctors, median ₹1,100 (range ₹300–3,500). Booking-site listings, checked 5 Oct 2026.
  11. Medicines Patent Pool. Tirzepatide: "The primary patent on tirzepatide has been granted in at least 37 LMICs, including India ... with an expected expiry in 2036"; formulation patents "filed and granted widely across LMICs and … expected to expire in 2039" (India not named for these). medicinespatentpool.org
  12. Cipla Ltd. Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes. Press release, 10 Dec 2025. cipla.com (PDF)
  13. Alkem Laboratories. Press release: launch of semaglutide in India, 21 Mar 2026. alkemlabs.com (PDF)
  14. European Medicines Agency. Mounjaro (tirzepatide) summary of product characteristics, sections 4.4, 4.6 and 4.8 (Table 1: nausea very common; cholelithiasis and acute pancreatitis uncommon; "not recommended during pregnancy"). EU label, not the Indian one. ema.europa.eu (PDF)
  15. Niva Bupa. All about the health insurance exclusion list updated from IRDAI ("Standard health insurance only pays out if you are admitted for medical treatment", unless the policy has an OPD benefit). Insurer article, checked 5 Oct 2026. nivabupa.com

Last checked 5 Oct 2026 · Next review due 5 Apr 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above. We checked each MRP on 5 Oct 2026 and used only printed MRPs, never a seller's discount price. Yearly figures are our arithmetic from those MRPs. It's general information, not medical advice. Talk to a qualified doctor before starting, stopping or changing any medicine. How we write